Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 237Recurrence 24Neoplasms, Plasma Cell 22Immunoglobulin Light-chain Amyloidosis 18Amyloidosis 10Smoldering Multiple Myeloma 8Lymphoma, Non-Hodgkin 5Lymphoma 5Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Plasma Cell 4Hodgkin Disease 4Sezary Syndrome 3Renal Insufficiency 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Plasmacytoma 3Neoplasms 3Nausea 3Mycosis Fungoides 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blast Crisis 3Vomiting 2Testicular Neoplasms 2

Interventions

siltuximab 3tocilizumab 2talquetamab 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Calcium Dobesilate × Plasma cell × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡